Zheng MM - Search Results

1

IMPDH inhibitors upregulate PD-L1 in cancer cells without impairing immune checkpoint inhibitor efficacy.

Zheng MM, Li JY, Guo HJ, Zhang J, Wang LS, Jiang KF, Wu HH, He QJ, Ding L, Yang B. Zheng MM, et al. Acta Pharmacol Sin. 2024 Nov 26. doi: 10.1038/s41401-024-01411-8. Online ahead of print. Acta Pharmacol Sin. 2024. PMID: 39592732

2

Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA.

Zhang W, Pan X, Xu Y, Guo H, Zheng M, Chen X, Wu H, Luan F, He Q, Ding L, Yang B. Zhang W, et al. Acta Pharm Sin B. 2023 Jun;13(6):2585-2600. doi: 10.1016/j.apsb.2023.04.002. Epub 2023 Apr 17. Acta Pharm Sin B. 2023. PMID: 37425040 Free PMC article.

3

The impact of lipids on the cancer-immunity cycle and strategies for modulating lipid metabolism to improve cancer immunotherapy.

Zheng M, Zhang W, Chen X, Guo H, Wu H, Xu Y, He Q, Ding L, Yang B. Zheng M, et al. Acta Pharm Sin B. 2023 Apr;13(4):1488-1497. doi: 10.1016/j.apsb.2022.10.027. Epub 2022 Nov 2. Acta Pharm Sin B. 2023. PMID: 37139414 Free PMC article. Review.

4

Erratum: Author correction to 'Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA' [Acta Pharmaceutica Sinica B 13 (2023) 2585-2600].

Zhang W, Pan X, Xu Y, Guo H, Zheng M, Chen X, Wu H, Luan F, He Q, Ding L, Yang B. Zhang W, et al. Acta Pharm Sin B. 2023 Oct;13(10):4337. doi: 10.1016/j.apsb.2023.07.023. Epub 2023 Jul 28. Acta Pharm Sin B. 2023. PMID: 37799392 Free PMC article.

5

Inhibitory effect of adenosine on adaptive antitumor immunity and intervention strategies.

Wang L, Zhang W, Zhang J, Zheng M, Pan X, Guo H, Ding L. Wang L, et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023 Sep 26;52(5):567-577. doi: 10.3724/zdxbyxb-2023-0263. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 37916308 Free PMC article. Review. Chinese, English.

6

Insights into the role of derailed endocytic trafficking pathway in cancer: From the perspective of cancer hallmarks.

Guo H, Zhou C, Zheng M, Zhang J, Wu H, He Q, Ding L, Yang B. Guo H, et al. Pharmacol Res. 2024 Mar;201:107084. doi: 10.1016/j.phrs.2024.107084. Epub 2024 Jan 29. Pharmacol Res. 2024. PMID: 38295915 Free article. Review.

7

Cediranib enhances the transcription of MHC-I by upregulating IRF-1.

Zhang J, Guo H, Wang L, Zheng M, Kong S, Wu H, Zhao L, Zhao Q, Yang X, He Q, Chen X, Ding L, Yang B. Zhang J, et al. Biochem Pharmacol. 2024 Mar;221:116036. doi: 10.1016/j.bcp.2024.116036. Epub 2024 Feb 1. Biochem Pharmacol. 2024. PMID: 38301967 Free article.

8

The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies.

Wang L, Zhang J, Zhang W, Zheng M, Guo H, Pan X, Li W, Yang B, Ding L. Wang L, et al. Acta Pharm Sin B. 2024 May;14(5):1951-1964. doi: 10.1016/j.apsb.2023.12.004. Epub 2023 Dec 16. Acta Pharm Sin B. 2024. PMID: 38799637 Free PMC article. Review.

9

Zosuquidar Promotes Antitumor Immunity by Inducing Autophagic Degradation of PD-L1.

Ding L, Guo H, Zhang J, Zheng M, Zhang W, Wang L, Du Q, Zhou C, Xu Y, Wu H, He Q, Yang B. Ding L, et al. Adv Sci (Weinh). 2024 Nov;11(41):e2400340. doi: 10.1002/advs.202400340. Epub 2024 Sep 4. Adv Sci (Weinh). 2024. PMID: 39229920 Free PMC article.

10

Ivacaftor, a CFTR potentiator, synergizes with osimertinib against acquired resistance to osimertinib in NSCLC by regulating CFTR-PTEN-AKT axis.

Li YK, Ge FJ, Liu XN, Zeng CM, Qian MJ, Li YH, Zheng MM, Qu JJ, Fang LJ, Lu JJ, Yang B, He QJ, Zhou JY, Zhu H. Li YK, et al. Among authors: zheng mm. Acta Pharmacol Sin. 2024 Dec 3. doi: 10.1038/s41401-024-01427-0. Online ahead of print. Acta Pharmacol Sin. 2024. PMID: 39627385

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

148 results

Search Page

Filters